Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2012-08-12 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Notice under section 708A of the Corporations Act 2 pages 87.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX release titled 'Notice Under Section 708A of the Corporations Act' regarding the issue of 100,000,000 ordinary shares by Imugene Limited. It references compliance with the Corporations Act and provides legal notice about the exemption for the sale of securities without disclosure. The document is short (2138 characters) and serves as a regulatory announcement about a share issue rather than a detailed financial report or capital raising update. It does not contain financial statements or detailed financing terms, so it is not a Capital/Financing Update (CAP). Instead, it fits best as a Regulatory Filing (RNS) because it is a compliance notice under securities law and does not fit other categories.
2012-08-12 English
Appendix 3B 7 pages 145.2KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of securities, issue price, purpose of the issue, and quotation application to the ASX. It references ASX rules and the Corporations Act warranties related to securities issuance and quotation. The document is a formal announcement of a new share issue and application for quotation of additional securities, consistent with regulatory filings for capital raising activities. It is not a full financial report, earnings release, or management discussion, but rather a specific announcement about new securities issuance and related compliance information. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (10,679 characters) and content confirm it is a substantive announcement, not merely a brief notice or report publication announcement.
2012-08-08 English
Details of Company Address 1 page 77.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX release dated 3 August 2012 announcing a change of the company's registered office address. It does not contain financial data, management discussion, voting results, or any report publication. The content is a straightforward regulatory announcement about administrative details, specifically the change of registered address. It is short (1484 characters) and does not reference any report being attached or published. This type of announcement fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2012-08-02 English
Board Appointment & New Direction 3 pages 282.4KB
Board/Management Information Classification · 95% confidence The document is a company announcement from Imugene about a new strategic direction and the appointment of a new board member, Steve Harris, who is a global pharma executive. The content focuses on the company's new drug delivery technology strategy, early monetisation plans, and details about the new board member's experience. There is no financial data, no mention of a report or filing, and no regulatory or compliance information. The document is clearly an announcement related to changes in the company's board and management structure, as well as strategic direction. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (7773 characters) supports that it is a full announcement rather than a brief notice or report publication announcement.
2012-07-31 English
Appendix 3X - Steve Harris Initial Directors Notice 2 pages 180.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, specifically for a director named Steve Harris. The content is focused on reporting personal shareholdings and interests of a company director, which aligns with insider trading or director dealings disclosures. The document length is 2372 characters, which is short and specific to director interests. Therefore, this document fits the category of Director's Dealing (DIRS).
2012-07-31 English
Quarterly Shareholder Update & Appendix 4C 7 pages 432.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'QUARTERLY SHAREHOLDER UPDATE June 2012' and includes detailed financial data for the quarter ended June 2012. It contains an Appendix 4C, which is a quarterly report format used by entities admitted on the basis of commitments, showing cash flows related to operating, investing, and financing activities, payments to directors, reconciliation of cash, and compliance statements. The document discusses financial results and operational updates for the quarter, including acquisition and financing activities. The length of the document (9878 characters) and the presence of substantive financial data and analysis confirm it is a financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2012
2012-07-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.